Archive · 24 May 2025
Sun Pharma to Invest $25M in Pharmazz Inc, Increasing Stake
Sun Pharma, a big medicine maker, is giving up to $25 million to a company called Pharmazz Inc.
This will let Sun Pharma own more of Pharmazz, about 22.7%.
Pharmazz is working on medicines, including ones to help people with a stroke or low blood volume.
The money will be given in two parts, with the first part happening soon.
Sun Pharma will also get the chance to sell one of Pharmazz's medicines in some countries.
Sun Pharmaceutical Industries Ltd. will invest up to USD 25 million in Pharmazz Inc.
The investment will increase Sun Pharma's stake to 22.7 percent.
The first tranche of USD 10 million will be invested by May 31, 2025.
Pharmazz Inc. is a biopharmaceutical company developing Sovateltide and Centhaquine.
Sun Pharma will have the option to negotiate licensing of Sovateltide for certain markets.
- Who
- Sun Pharmaceutical Industries Ltd and Pharmazz Inc.
- What
- Sun Pharma is investing up to USD 25 million in Pharmazz Inc.
- When
- Investment tranches on or before May 31, 2025 and November 30, 2025
- Where
- USA (Pharmazz Inc. location)
- Why
- To increase its stake and potentially license and distribute Pharmazz's drug, Sovateltide, in developed markets.
- Total Investment
- USD 25 million
- Stake Increase
- 22.7 percent
- Pharmazz Inc. Location
- US-based
- Drug Candidates' Target Diseases
- Acute cerebral ischemic stroke and hypovolemic shock
- Drug Candidate Names
- Sovateltide and Centhaquine
- Drug Approvals
- India